MX2017016517A - Composiciones estables al almacenamiento y metodos para el tratamiento de errores de refraccion del ojo. - Google Patents
Composiciones estables al almacenamiento y metodos para el tratamiento de errores de refraccion del ojo.Info
- Publication number
- MX2017016517A MX2017016517A MX2017016517A MX2017016517A MX2017016517A MX 2017016517 A MX2017016517 A MX 2017016517A MX 2017016517 A MX2017016517 A MX 2017016517A MX 2017016517 A MX2017016517 A MX 2017016517A MX 2017016517 A MX2017016517 A MX 2017016517A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- storage stable
- eye
- refractive errors
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 208000014733 refractive error Diseases 0.000 title abstract 2
- 229960003216 aceclidine Drugs 0.000 abstract 3
- WRJPSSPFHGNBMG-UHFFFAOYSA-N acetic acid 1-azabicyclo[2.2.2]octan-3-yl ester Chemical compound C1CC2C(OC(=O)C)CN1CC2 WRJPSSPFHGNBMG-UHFFFAOYSA-N 0.000 abstract 3
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 229940124570 cycloplegic agent Drugs 0.000 abstract 1
- 239000000634 cycloplegic agent Substances 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
La invención provee composiciones y métodos para lograr aceclidina estable al almacenamiento; las composiciones comprenden preferiblemente aceclidina, un agente ciclopléjico, un tensoactivo, un ajustador de la tonicidad y opcionalmente un potenciador de la viscosidad y un antioxidante; la invención proporciona además métodos para tratar errores de refracción del ojo con una composición de acetilidina estable al almacenamiento.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/742,903 US9320709B2 (en) | 2013-08-28 | 2015-06-18 | Storage stable compositions and methods for the treatment of refractive errors of the eye |
US14/742,921 US9314427B2 (en) | 2013-08-28 | 2015-06-18 | Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye |
PCT/US2016/036687 WO2016205068A1 (en) | 2015-06-18 | 2016-06-09 | Storage stable compositions and methods for the treatment of refractive errors of the eye |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017016517A true MX2017016517A (es) | 2018-05-28 |
Family
ID=57545598
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017016517A MX2017016517A (es) | 2015-06-18 | 2016-06-09 | Composiciones estables al almacenamiento y metodos para el tratamiento de errores de refraccion del ojo. |
MX2017016518A MX2017016518A (es) | 2015-06-18 | 2016-06-09 | Composiciones y metodos para la mejora de la vision a distancia y el tratamiento de errores de refraccion del ojo. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017016518A MX2017016518A (es) | 2015-06-18 | 2016-06-09 | Composiciones y metodos para la mejora de la vision a distancia y el tratamiento de errores de refraccion del ojo. |
Country Status (9)
Country | Link |
---|---|
EP (2) | EP3310336A4 (es) |
JP (3) | JP6835747B2 (es) |
KR (4) | KR20180014825A (es) |
CN (3) | CN116808032A (es) |
AU (2) | AU2016280615B2 (es) |
CA (2) | CA2987787C (es) |
HK (1) | HK1254338A1 (es) |
MX (2) | MX2017016517A (es) |
WO (2) | WO2016205069A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180014825A (ko) * | 2015-06-18 | 2018-02-09 | 프레스바이오피아 세라피스, 엘엘씨 | 눈의 굴절 이상 치료 및 원거리 시력 개선용 조성물 및 방법 |
CN110505876A (zh) * | 2017-03-23 | 2019-11-26 | 新加坡保健服务集团 | 包含噻托铵作为活性成分的用于预防近视、治疗近视、及/或预防近视进展的药剂 |
CA3063228C (en) | 2017-05-11 | 2022-06-28 | Nevakar Inc. | Atropine pharmaceutical compositions |
EP4228636A1 (en) * | 2020-10-13 | 2023-08-23 | Lenz Therapeutics, Inc. | Compositions and methods for storage stable ophthalmic drugs |
AU2021369566A1 (en) * | 2020-11-02 | 2023-06-22 | Visus Therapeutics, Inc. | Degradant compound in a medicament |
EP4308080A1 (en) * | 2021-03-16 | 2024-01-24 | Vyluma Inc. | Multi-dose container for ophthalmic compositions |
KR20220154509A (ko) | 2021-05-13 | 2022-11-22 | 전연우 | 복용 시간을 알려주고 편하게 약을 꺼낼 수 있는 약통 |
TW202333700A (zh) * | 2021-12-16 | 2023-09-01 | 美商倫茨治療公司 | 用於治療眼病之組成物及方法 |
KR20230126461A (ko) * | 2022-02-23 | 2023-08-30 | 주식회사 스카이테라퓨틱스 | 고분자 히알루론산의 구조체, 이의 제조방법 및 이를 포함하는 화장료 조성물 |
KR20230126522A (ko) * | 2022-02-23 | 2023-08-30 | 주식회사 스카이테라퓨틱스 | 고분자 히알루론산의 구조체, 이의 제조방법 및 이를 포함하는 점안 조성물 |
WO2023172240A1 (en) * | 2022-03-07 | 2023-09-14 | Harrow Ip, Llc | Extended-release pharmaceutical compositions for treating eye conditions |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4474751A (en) * | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
US6291466B1 (en) | 1998-07-30 | 2001-09-18 | Allergan Sales, Inc. | Cholinergic agents in the treatment of presbyopia |
BR0015416A (pt) * | 1999-11-09 | 2002-07-16 | Alcon Inc | Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos |
ITMI20010708A1 (it) * | 2001-04-03 | 2002-10-03 | Alessandro Randazzo | Trattamento farmacologico degli aloni notturni e delle immagini fantasma con parasimpaticomimetici diluiti aceclidina/pilocarpina dopo inter |
JP5583310B2 (ja) * | 2002-12-20 | 2014-09-03 | チャクシュ・リサーチ・インコーポレーテッド | 眼球の症状の予防及び治療のための眼科用製剤 |
US20060177430A1 (en) * | 2002-12-20 | 2006-08-10 | Chakshu Research Inc | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer |
US20050196370A1 (en) * | 2003-03-18 | 2005-09-08 | Zhi-Jian Yu | Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye |
DE602006008643D1 (de) | 2006-12-18 | 2009-10-01 | Jorge Luis Benozzi | Ophthalmische Zusammensetzungen von parasympathischen Stimulantia und Entzündungshemmer zur Verwendung bei der Behandlung von Presbyopie |
WO2009072007A2 (en) * | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
CA2849366C (en) | 2011-09-20 | 2019-09-10 | Juan Carlos Abad | Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism |
MY171920A (en) * | 2011-10-12 | 2019-11-07 | Ascendis Pharma Ophthalmology Div A/S | Prevention and treatment of ocular conditions |
US20140378401A1 (en) * | 2013-06-21 | 2014-12-25 | Gnt, Llc | Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations |
US9573840B2 (en) * | 2013-08-27 | 2017-02-21 | Corning Incorporated | Antimony-free glass, antimony-free frit and a glass package that is hermetically sealed with the frit |
US9089562B2 (en) * | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
KR20180014825A (ko) | 2015-06-18 | 2018-02-09 | 프레스바이오피아 세라피스, 엘엘씨 | 눈의 굴절 이상 치료 및 원거리 시력 개선용 조성물 및 방법 |
-
2016
- 2016-06-09 KR KR1020187000612A patent/KR20180014825A/ko not_active IP Right Cessation
- 2016-06-09 AU AU2016280615A patent/AU2016280615B2/en active Active
- 2016-06-09 KR KR1020187000609A patent/KR102598047B1/ko active IP Right Grant
- 2016-06-09 MX MX2017016517A patent/MX2017016517A/es active IP Right Grant
- 2016-06-09 KR KR1020237018669A patent/KR20230085217A/ko active IP Right Grant
- 2016-06-09 WO PCT/US2016/036692 patent/WO2016205069A1/en active Application Filing
- 2016-06-09 CA CA2987787A patent/CA2987787C/en active Active
- 2016-06-09 CN CN202310360068.XA patent/CN116808032A/zh active Pending
- 2016-06-09 CN CN201680035682.7A patent/CN107847492B/zh active Active
- 2016-06-09 JP JP2017565201A patent/JP6835747B2/ja active Active
- 2016-06-09 EP EP16812173.9A patent/EP3310336A4/en active Pending
- 2016-06-09 WO PCT/US2016/036687 patent/WO2016205068A1/en active Application Filing
- 2016-06-09 KR KR1020237037557A patent/KR20230156161A/ko active Search and Examination
- 2016-06-09 EP EP16812174.7A patent/EP3310356A4/en active Pending
- 2016-06-09 MX MX2017016518A patent/MX2017016518A/es active IP Right Grant
- 2016-06-09 AU AU2016280616A patent/AU2016280616B2/en active Active
- 2016-06-09 CN CN201680035276.0A patent/CN107920984A/zh active Pending
- 2016-06-09 JP JP2017565154A patent/JP6838712B2/ja active Active
- 2016-06-09 CA CA2987783A patent/CA2987783A1/en active Pending
-
2018
- 2018-10-18 HK HK18113414.1A patent/HK1254338A1/zh unknown
-
2020
- 2020-10-20 JP JP2020175809A patent/JP7026189B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP3310356A1 (en) | 2018-04-25 |
KR20230085217A (ko) | 2023-06-13 |
CN107847492B (zh) | 2021-05-25 |
CN107920984A (zh) | 2018-04-17 |
JP6835747B2 (ja) | 2021-02-24 |
MX2017016518A (es) | 2018-05-28 |
CA2987783A1 (en) | 2016-12-22 |
HK1254338A1 (zh) | 2019-07-19 |
JP2021035954A (ja) | 2021-03-04 |
AU2016280616B2 (en) | 2020-10-22 |
CA2987787C (en) | 2023-06-27 |
KR20180014825A (ko) | 2018-02-09 |
BR112017025722A2 (pt) | 2018-08-07 |
EP3310336A1 (en) | 2018-04-25 |
KR20180014824A (ko) | 2018-02-09 |
KR20230156161A (ko) | 2023-11-13 |
JP7026189B2 (ja) | 2022-02-25 |
AU2016280615A1 (en) | 2017-12-14 |
CN107847492A (zh) | 2018-03-27 |
EP3310336A4 (en) | 2018-12-05 |
CA2987787A1 (en) | 2016-12-22 |
JP2018517738A (ja) | 2018-07-05 |
JP2018517740A (ja) | 2018-07-05 |
WO2016205069A1 (en) | 2016-12-22 |
AU2016280615B2 (en) | 2020-10-01 |
AU2016280616A1 (en) | 2017-12-14 |
KR102598047B1 (ko) | 2023-11-06 |
EP3310356A4 (en) | 2018-12-05 |
BR112017025726A2 (pt) | 2018-08-14 |
CN116808032A (zh) | 2023-09-29 |
WO2016205068A1 (en) | 2016-12-22 |
JP6838712B2 (ja) | 2021-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017016517A (es) | Composiciones estables al almacenamiento y metodos para el tratamiento de errores de refraccion del ojo. | |
MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
MX2018006217A (es) | Agonistas del receptor de apelina y metodos de uso. | |
MX2020002922A (es) | Composiciones y metodos para el tratamiento de la presbicia. | |
MX2021002455A (es) | Metodos para tratar tumores de celulas epitelioides. | |
MX2018009773A (es) | Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4). | |
MX2017017157A (es) | Composiciones de bebida lista para beber estables que comprende agentes activos lipofilos. | |
MX2020005213A (es) | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. | |
MX2018006632A (es) | Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4). | |
IL273300A (en) | High dose valbenazine formulation and related preparations, methods and kits | |
MX2018016057A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
MX2023006706A (es) | Administracion transdermica de agentes grandes en composiciones de emulsion mediante acondicionamiento de la piel con microagujas y sus usos. | |
MY186271A (en) | Ophthalmic compositions and methods of use therefor | |
NZ720769A (en) | Anti-siglec-8 antibodies and methods of use thereof | |
NZ763528A (en) | Heterocyclic gpr119 agonist compounds | |
EA201790787A1 (ru) | Снижение вязкости фармацевтических составов | |
MX2018011300A (es) | Composiciones y metodos para el tratamiento de la presbicia. | |
MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
MX2017008390A (es) | Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato. | |
EP3274548A4 (en) | METHODS AND COMPOSITIONS FOR INJECTING ACTIVE SOLUTIONS OF HIGH CONCENTRATION AND / OR HIGH VISCOSITY | |
PH12017501864A1 (en) | Compositions and methods for treating autism | |
EP4234552A3 (en) | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | |
EA201992170A1 (ru) | Модуляторы экспрессии pcsk9 | |
MX2021006326A (es) | Inhibidores de pcna. | |
PH12017501022A1 (en) | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |